Ionis Pharmaceuticals Reports Q2 Revenue Growth Amid TRYNGOLZA Launch and Phase III Trial Outcome
Ionis Pharmaceuticals reported second-quarter revenue of $268 million in July 2026, with commercial revenue reaching $119 million. The growth was driven by DAWNZERA sales and the early launch of TRYNGOLZA for severe hypertriglyceridemia (sHTG), which generated $5 million in Q2 product sales. Ionis reaffirmed its full-year 2026 revenue outlook between $875 million to $900 million, with expectations that TRYNGOLZA could reach annual sales of up to $110 million and DAWNZERA up to $120 million. The company noted a setback in the phase III ATTR cardiomyopathy trial for eplontersen, which failed to meet its primary endpoint. However, it observed TTR reductions and nominally significant results within monotherapy subgroups. Ionis is awaiting detailed data while advancing other pipeline candidates like zilganersen and pelacarsen. Ionis ended the quarter with $2.1 billion in cash and investments and expects operating expenses to rise modestly through 2026, projecting a non-GAAP operating loss of between $425 million to $475 million.
Tickers: $IONS
Topics: biotech drug development financial results pharmaceuticals